Nirmatrelvir

MECHANISM OF ACTION

Nirmatrelvir works by selectively inhibiting the SARS-CoV-2 main protease (3CLpro/Mpro), an enzyme essential for viral replication. This protease normally cleaves viral polyproteins into functional proteins needed for virus assembly. By blocking this enzyme, nirmatrelvir prevents the virus from processing its proteins, thereby stopping replication and reducing viral load in infected patients.

PHARMACOKINETICS

Absorption

Nirmatrelvir is well absorbed after oral administration, but it is co-administered with ritonavir (as in Paxlovid) to increase its plasma concentration by inhibiting CYP3A4-mediated metabolism. Food does not have a clinically significant effect on its overall absorption, so it can be taken with or without meals. Peak plasma levels are typically reached within a few hours.

Distribution

Nirmatrelvir is moderately distributed in the body after absorption, with plasma protein binding of about 70%, mainly to albumin. It distributes into respiratory tissues, where SARS-CoV-2 primarily replicates, allowing effective antiviral action. Its distribution is enhanced and maintained by co-administration with ritonavir, which increases systemic exposure by inhibiting its metabolism.

Metabolism

Nirmatrelvir is primarily metabolized in the liver via CYP3A4-mediated oxidation, leading to inactive metabolites. Because it is extensively metabolized by CYP3A4, it is co-administered with ritonavir, a strong CYP3A4 inhibitor, which slows its breakdown and increases its plasma concentration and duration of action. This pharmacokinetic boosting is essential for maintaining therapeutic antiviral levels.

Elimination

Nirmatrelvir is eliminated mainly through renal excretion, with a large proportion of the drug excreted unchanged in urine. A smaller amount is eliminated as metabolites in feces via biliary excretion. Its elimination is significantly influenced by co-administration with ritonavir, which prolongs its half-life by inhibiting CYP3A4 metabolism.

PHARMACODYNAMICS

Nirmatrelvir produces its pharmacodynamic effect by selectively inhibiting the SARS-CoV-2 main protease (Mpro/3CL protease), an enzyme essential for viral replication. By blocking this protease, it prevents cleavage of viral polyproteins into functional units, thereby halting formation of essential viral proteins. This stops viral replication, reduces viral load, and helps limit progression of COVID-19, especially when given early in infection.

ADMINISTRATION

Nirmatrelvir is administered orally in combination with ritonavir (as Paxlovid). It is taken as tablets, usually twice daily for 5 days. The tablets should be swallowed whole with or without food, and the dosing schedule must be followed strictly at 12-hour intervals for optimal antiviral effect.

DOSAGE AND STRENGTH

Nirmatrelvir is available only in fixed combination with ritonavir as Paxlovid.

• Strength per dose pack: 

  • Nirmatrelvir 150 mg tablets (2 tablets per dose = 300 mg) 

  • Ritonavir 100 mg (1 tablet per dose) 

• Usual adult dosage: 

  • 300 mg nirmatrelvir + 100 mg ritonavir, taken twice daily for 5 days 

• Dose adjustment: 

  • Reduced dose is used in patients with moderate renal impairment

DRUG INTERACTIONS

Nirmatrelvir has important drug interactions mainly due to its co-administration with ritonavir, a strong CYP3A4 inhibitor.

Key interactions:

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) → greatly reduce effectiveness (contraindicated)

• CYP3A4 substrates (e.g., certain statins like simvastatin, midazolam, amiodarone) → increased drug levels and toxicity risk

• Anticoagulants (e.g., warfarin) → altered anticoagulant effect, requires monitoring

FOOD INTERACTIONS

Nirmatrelvir has no significant food interactions and can be taken with or without food. Food does not affect its effectiveness, though taking it with meals may improve stomach comfort in some patients.

CONTRAINDICATIONS

Nirmatrelvir is contraindicated in patients with hypersensitivity to the drug or ritonavir. It should not be used with strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John’s wort) or with drugs highly dependent on CYP3A metabolism where toxicity can occur. 

SIDE EFFECTS

• Altered taste (dysgeusia)

• Abdominal pain

• Fatigue

• Elevated liver enzymes (rare)

• Allergic reactions (rare)

OVER DOSAGE

Nirmatrelvir overdose may cause increased side effects such as nausea, vomiting, diarrhea, headache, dizziness, abdominal pain, and possible liver enzyme elevation

TOXICITY

Nirmatrelvir toxicity mainly results in exaggerated adverse effects such as nausea, vomiting, diarrhea, headache, dizziness, and abdominal discomfort, along with possible elevation of liver enzymes. It may also increase the risk of drug interactions due to CYP3A4 inhibition from ritonavir. Management is supportive with drug discontinuation and monitoring.